Selective Delivery of Clinically Approved Tubulin Binding Agents through Covalent Conjugation to an Active Targeting...

Area of Science:

• Oncology
• Pharmacology
• Drug Development

Background:

• Most anticancer agents, including tubulin binding agents, lack specificity for cancer cells, leading to side effects.
• Actively targeted drug conjugates aim to enhance specificity by covalently linking drugs to cancer-targeting moieties.
• These conjugates are designed for increased uptake by cancer cells and reduced uptake by normal cells, improving therapeutic outcomes.

Purpose of the Study:

• To discuss recent strategies for creating actively targeted drug conjugates.
• To evaluate the success of various targeting approaches for improving drug specificity and patient tolerability.

Main Methods:

• Review of strategies involving conjugation of tubulin binding agents to targeting molecules like small molecules, polysaccharides, peptides, proteins, and antibodies.
• Analysis of targeting mechanisms that exploit receptor overexpression on cancer cells.
• Examination of clinical approval data and pre-clinical/early-stage clinical study results for different conjugate types.

Main Results:

• Antibody-targeted strategies have demonstrated significant success, with six agents achieving clinical approval.
• Conjugates targeting the folate receptor show promising efficacy and toxicity profiles in pre-clinical and early clinical studies.
• Various other targeting approaches are under investigation for their potential to improve cancer therapy.

Conclusions:

• Actively targeted drug conjugates represent a promising strategy to overcome the specificity limitations of traditional anticancer agents.
• Antibody-drug conjugates are currently the most successful type of actively targeted conjugate in clinical practice.
• Continued research into novel targeting moieties and conjugation strategies is essential for advancing cancer treatment.